Quest Diagnostics Acquires Laboratory Services Business

Oxford Immunotec's T-SPOT®.TB Tuberculosis and Accutix™ Tick-Borne Disease Testing Services are Part of Quest Diagnostics' Portfolio of Innovative Infectious Disease Diagnostics Tests, Broadening Access in the United States

On Nov 7, 2018

Secaucus-based Quest Diagnostics and Oxford Immunotec Global PLC announced that Quest Diagnostics has completed its previously announced acquisition of the U.S. laboratory services business of Oxford Immunotec.

The T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest Diagnostics’ portfolio of innovative infectious disease testing services. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest Diagnostics under the terms of a long-term supply agreement. In addition, the parties have entered into a strategic collaboration agreement to drive continued growth of T-SPOT.TB testing in the U.S.

Quest Diagnostics intends to continue to offer QuantiFERON TB testing services to provide physicians choice in blood-based TB testing.

About Blood-Based TB Testing

The T-SPOT.TB test is an interferon-gamma release assay (IGRA) that is intended for use as an aid in the diagnosis of Mycobacterium tuberculosis infection and disease. As many as 13 million cases of latent TB may exist in the U.S.i The Infectious Diseases Society of America (IDSA) and other medical associations recommend blood-based IGRA TB testing over traditional skin testing for certain patient populations, citing relative accuracy and the ability to perform IGRA testing with one office visit.

To access more business news, visit NJB News Now.

Related Articles: